Severe Eosinophilic Asthma
18
1
3
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.6%
1 terminated out of 18 trials
90.0%
+3.5% vs benchmark
17%
3 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (18)
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma
Clock Proteins as Prognostic Markers
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
Real World Study With Benralizumab in Severe Asthma in Switzerland
Severe Asthma, MepolizumaB and Affect: SAMBA Study
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma